Investor Overview

Molecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate the function of RNA and underexplored protein targets to treat multiple incurable diseases.

We have generated a diverse pipeline of seven distinct programs with the support of leading academic life science institutions globally, including Yale University, Rutgers University, the VIB Gent, the University of Michigan, and more recently the International Institute of Molecular and Cell Biology in Warsaw (IIMCB), which has significant expertise in RNA science.

Our most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases such as sarcoidosis and idiopathic pulmonary fibrosis that is Phase II ready. Molecure expects to start a Phase II trial in patients with sarcoidosis in 2023.

Our second proprietary candidate is OATD-02, an oral, potent and selective first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer, which is expected to advance to Phase I clinical development in the second half of 2022.

Investor Overview

Our Business Model

  • Our business model is based on successfully building a pipeline of small molecule drug candidates both internally and via selective in-licensing deals. We then plan to partner with global pharmaceutical and biotechnology companies for further clinical development and/or commercialization. The preferred stage of development for out-licensing is early clinical Proof of Concept.
  • Our partnerships with top global academic research institutes, combined with our exceptional capabilities in medicinal chemistry and translational science, have allowed the company to access the untapped, first/best-in-class novel biology targets – both mRNA and proteins – needed to generate a pipeline of first-in-class drug candidates.
  • Our approach to drug discovery is based on bold target selection, both mRNA and proteins, traditionally undrugged by small molecules, with limited competition. Drug candidates developed using this approach have attractive commercial potential and will address disease areas with significant unmet medical needs.
  • Our entrepreneurial/risk taking approach allows us to successfully work on challenging, high reward targets given our preferential access to the highly regarded and rapidly growing pool of Polish top life science talent.

 

Investor's calendar

DATE EVENT
March 31, 2022Publication of the Company's Annual Reports for the year 2021 (separate and consolidated)
April 29, 2022Publication of the Company’s 1st quarter 2022 report
September 30, 2022Publication of the Company’s half year 2022 report
October 31, 2022Publication of the Company’s 3rd quarter 2022 report

Stock Quotes


Shareholding Structure

Shareholders

 NUMBER OF SHARESNOMINAL VALUE OF SHARESSHARE IN THE SHARE CAPITALSHARE IN THE NUMBER OF VOTES
BLACK FOREST SICAV - SIF societe anonyme 4 135 00041 350,0029,47%29,47%
Szumowski Investments Sp. z o.o.1 010 00010 100,007,20%7,20%
Marcin Szumowski117 1631 171,630,84%0,84%
Marcin Szumowski together with Szumowski Investments Sp. z o.o.1 127 16311 271,638,04%8,04%
Nationale-Nederlanden Universal Pension Society SA845 8198 458,196,03%6,03%
Others7 922 01879 220,1856,46%56,46%
TOTAL14 030 000140 300,00100,00%100,00%

* Members of the Management Board, Supervisory Board and shareholders of the Company do not hold any shares of BLACK FOREST SICAV-SIF societe anonyme. The indirect owner of the shares is Michał Andrzej Sołowow.

Share in capital and number of votes

Marcin Szumowski together with Szumowski Investments sp. Z oo Nationale-Nederlanden Universal Pension Society SA BLACK FOREST SICAV - SIF societe anonyme * Other

Financial Information

Financial Report

ON the WSE FROM

April 19, 2018

MARKET / QUOTATION SEGMENT

WSE / Parallel

SECTOR (WSE)

Biotechnology

INDEX AFFILIATION

WIG-Poland, WIG

WSE TICKER

MOC

ISIN

PLONCTH00011

NUMBER OF SHARES ISSUED

14 030 000

Contact

Contact with the media and individual investors

Michał Wierzchowski

CC GROUP

+48 531 613 067 +48 531 613 067
michal.wierzchowski@ccgroup.pl

Contact with institutional investors and sell-side analysts

Katarzyna Mucha

CC GROUP

+48 697 613 712 +48 22 440 1 440
katarzyna.mucha@ccgroup.pl
This site is registered on wpml.org as a development site.